Goldman Sachs’s Denali Therapeutics DNLI Stock Holding History

Goldman Sachs’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-30,000	Closed	-$2.35M	–	6285
2021 Q2	$2.35M	Buy	+30,000	New	+$1.86M	﹤0.01%	4050

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return

Goldman Sachs's DNLI Position: Q2 2026 in Review

Goldman Sachs reduced its Denali Therapeutics (DNLI) stake by 5.7% in Q2 2026, selling an estimated $5.16M and leaving 4,155,895 shares worth $107M. The position accounts for 0.01% of the portfolio, ranked #1175.

Goldman Sachs first reported a position in DNLI in Q4 2017 and has held it in 35 quarters since. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Goldman Sachs held 4,155,895 shares of Denali Therapeutics worth $107M as of Q2 2026.
Goldman Sachs sold 251,360 Denali Therapeutics shares in Q2 2026, an estimated $5.16M.
Denali Therapeutics made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #1175 holding.
Goldman Sachs first reported a position in Denali Therapeutics in Q4 2017 and has held it in 35 quarters since.
294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.